Rifaximin treatment in hepatic encephalopathy.

By N. Bass, K. Mullen, A. Sanyal, F. Poordad, G. Neff, C. Leevy, S. Sigal, M. Sheikh, K. Beavers, Todd Frederick and 7 more. New England Journal of Medicine, 2010

630 citations recorded by the source corpus.

Subfields: Hepatology, Public Health, Environmental and Occupational Health, Surgery

View Paper: https://www.semanticscholar.org/paper/305b3f59f203e4df16f60e089dcdb8905ffe1689

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hepatology

1. M. Bernardi
2. Aleksander Krag
3. C. Francoz
4. C. Villanueva
5. J. Trebicka
6. W. Laleman
7. P. Ginés
8. P. Angeli

In Surgery

1. P. Ginés

Citations in the corpus

• EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. (2018, background): “Many patients receive rifaximin to prevent recurrent episodes of hepatic encephalopathy [284].”